Clinical TrialsThe first complete response in the MDNA11 and pembrolizumab combination study was observed in a patient with advanced anal squamous cell carcinoma.

Financial StabilityThe cash runway for Medicenna Therapeutics extends into mid-calendar 2026, supporting its financial stability.

Bears Say

Efficacy ConcernsAlthough the combo data is promising, it is too early to determine efficacy.

Response RatesThe overall response rate for the Medicenna pembro combo in solid tumors is low at 22%.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

9.13% Insiders

―

Mutual Funds

0.17% Other Institutional Investors

90.70% Public Companies and

Individual Investors

Detailed Ownership Overview >

MDNA FAQ

What was Medicenna Therapeutics Corp’s price range in the past 12 months?

Medicenna Therapeutics Corp lowest stock price was C$0.78 and its highest was C$2.63 in the past 12 months.

What is Medicenna Therapeutics Corp’s market cap?

Medicenna Therapeutics Corp’s market cap is C$57.71M.

When is Medicenna Therapeutics Corp’s upcoming earnings report date?

Medicenna Therapeutics Corp’s upcoming earnings report date is Aug 07, 2025 which is in 9 days.

How were Medicenna Therapeutics Corp’s earnings last quarter?

Medicenna Therapeutics Corp released its earnings results on Jun 26, 2025. The company reported C$0.02 earnings per share for the quarter, beating the consensus estimate of -C$0.06 by C$0.08.

Is Medicenna Therapeutics Corp overvalued?

According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Medicenna Therapeutics Corp pay dividends?

Medicenna Therapeutics Corp does not currently pay dividends.

What is Medicenna Therapeutics Corp’s EPS estimate?

Medicenna Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicenna Therapeutics Corp have?

Medicenna Therapeutics Corp has 68,697,876 shares outstanding.

What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?

Medicenna Therapeutics Corp reported an EPS of C$0.02 in its last earnings report, beating expectations of -C$0.06. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?

Currently, no hedge funds are holding shares in TSE:MDNA

Medicenna Therapeutics Corp Stock Smart Score

Underperform

Fundamentals

Return on Equity

-97.22%

Trailing 12-Months

Asset Growth

48.33%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medicenna Therapeutics Corp

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.